"We Remain Focused on Advancing Our Late-Stage Oncology Product Candidates Towards Potential Registration," Said BioNTech's CEO Ugur Sahin.Nov 4 (Reuters) - German Drugmaker BioNTech 22Uay.de on Monday Lowered Its Guidance for Full-Year Revenue, Citing Covid-19 Uptake and Price Levels, Inventory Write-Downs and Pfizer Pfe.n Charges.
11月4日（路透社）— 德國製藥商BioNTech 22uay.de 週一下調了全年收入預期，理由是Covid-19的吸收量和價格水平、庫存減記和輝瑞公司 Pfe.n 收費。
The Company Now Expects 2024 Revenue to Be at the Low End of the Guidance Range of 2.5 to 3.1 Billion Euros ($2.72 - $3.38 Billion).
該公司現在預計，2024年的收入將處於2.5至31歐元（27.2億美元至33.8億美元）指導區間的低端。
BioNTech, Whose Covid-19 Vaccine in Partnership With Pfizer Was Widely Used During the Pandemic, Reported Third-Quarter Revenue of 1.24 Billion Euros Compared to 895.3 Million Euros Year Ago, Helped by Earlier Approvals for Its Variant-Adapted Covid-19 Vaccines.
BioNTech與輝瑞合作的Covid-19疫苗在大流行期間被廣泛使用。該公司報告稱，第三季度收入爲12.4歐元，而去年同期爲89530萬歐元，這得益於其變體改造的Covid-19疫苗早些時候獲得批准。
In August, the Mainz-Based Company Said Some 90% of Its Total Research and Development Spending Was Going Towards Non-Covid Related Activities, Mainly Oncology and Mrna.
在八月，這家總部位於美因茲的公司表示，其研發總支出中約有90％用於與Covid無關的活動，主要是腫瘤學和Mrna。
"We Remain Focused on Advancing Our Late-Stage Oncology Product Candidates Towards Potential Registration," Said BioNTech's CEO Ugur Sahin.
BioNTech首席執行官烏古爾·薩欣說：「我們仍然專注於推動我們的後期腫瘤學候選產品向潛在註冊邁進。」
The Company Is Aiming for Its First Oncology Launch in 2026.
該公司的目標是在2026年推出首次腫瘤學。
($1 = 0.9176 Euros)
($1 = 0.9176 歐元)
(Reporting by Anastasiia Kozlova and Amir Orusov, Editing by Rachel More)
（阿納斯塔西婭·科茲洛娃和阿米爾·奧魯索夫的報道，雷切爾·莫爾編輯）
